X4 Pharmaceuticals price target raised to $7 from $1.50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on X4 Pharmaceuticals (XFOR) to $7 from $1.50 and keeps a Buy rating on the shares following the Q1 report. The company is on track to complete enrollment in the Phase 3 4WARD study evaluating mavorixafor with or without constant doses of G-CSF in congenital, idiopathic, and autoimmune chronic neutropenia by Q4, the analyst tells investors in a research note.